Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in... | January 4, 2023
/PRNewswire/ --Research findings being presented during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition challenge standard...
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...